CREBBP and telomere syndrome: Furthermore, the combination of PRI-724 with conventional chemotherapeutic agents used in the treatment of metastatic STS, such as doxorubicin and trabectedin, increased their antitumoral effects in a synergistic manner, suggesting that CBP/β-catenin inhibitors, such as PRI-724, could also be a promising therapeutic option for STS patients, and should be further evaluated.